EGFR and non-small cell lung carcinoma: Thus, this study retrospectively reviewed patients in the last 5 years and included 849 NSCLC patients to investigate whether or not 18F–FDG PET could be a valuable method for predicting EGFR mutations and the ALK rearrangement in NSCLC.